Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Characterization and evaluation of an oral microemulsion containing the antitumor diterpenoid compound ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid

Authors Lu Y, Wu K, Li L, He Y, Cui L, Liang N, Mu B

Received 22 December 2012

Accepted for publication 29 January 2013

Published 10 May 2013 Volume 2013:8(1) Pages 1879—1886

DOI https://doi.org/10.2147/IJN.S42002

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yingnian Lu,1,2 Kefeng Wu,2 Li Li,2 Yuhui He,2 Liao Cui,2 Nianci Liang,2 Bozhong Mu1

1Department of Chemistry, East China University of Science and Technology, Shanghai, 2Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical College, Zhanjiang, People’s Republic of China

Abstract: The objective of this study was to develop an oral microemulsion formulation of the antitumor diterpenoid agent, ent-11a-hydroxy-15-oxo-kaur-16-en-19-oic- acid (henceforth referred to as 5F), to enhance its bioavailability and evaluate its hepatotoxicity. Pseudoternary phase diagrams showed that the optimal microemulsion formulation contained 45% water, 10% castor oil as the oil phase, 15% Cremophor EL as the surfactant, and 30% as a cosurfactant mixture of 1,2-propanediol and polyethylene glycol (PEG)-400 (2:1, w/w). The microemulsion preparation was characterized and its droplet diameter was within 50 nm. Release of 5F in vitro from the microemulsion was slightly increased compared with a suspension containing the same amount of active drug. Pharmacokinetic parameters in vivo indicated that bioavailability was markedly improved, with the relative bioavailability being 616.15% higher for the microemulsion than for the suspension. Toxicity tests showed that the microemulsion had no hepatotoxicity in mice. These results suggest the potential for 5F microemulsion to be administered by the oral route.

Keywords: antitumor, diterpenoid, microemulsion, pharmacokinetics, toxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Enhanced penetration into 3D cell culture using two and three layered gold nanoparticles

England CG, Priest T, Zhang G, Sun X, Patel DN, McNally LR, van Berkel V, Gobin AM, Frieboes HB

International Journal of Nanomedicine 2013, 8:3603-3617

Published Date: 1 October 2013

Design of indomethacin-loaded nanoparticles: effect of polymer matrix and surfactant

Dupeyrón D, Kawakami M, Ferreira AM, Cáceres-Vélez PR, Rieumont J, Azevedo RB, Carvalho JCT

International Journal of Nanomedicine 2013, 8:3467-3477

Published Date: 13 September 2013

Advances in drug delivery via electrospun and electrosprayed nanomaterials

Zamani M, Prabhakaran MP, Ramakrishna S

International Journal of Nanomedicine 2013, 8:2997-3017

Published Date: 9 August 2013

Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent

Kanakia S, Toussaint JD, Mullick Chowdhury S, Lalwani G, Tembulkar T, Button T, Shroyer KR, Moore W, Sitharaman B

International Journal of Nanomedicine 2013, 8:2821-2833

Published Date: 5 August 2013

Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics

Chen J, Shao R, Zhang XD, Chen C

International Journal of Nanomedicine 2013, 8:2677-2688

Published Date: 24 July 2013

Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration

Abdelwahab SI, Sheikh BY, Taha MME, How CW, Abdullah R, Yagoub U, El-Sunousi R, Eid EEM

International Journal of Nanomedicine 2013, 8:2163-2172

Published Date: 17 June 2013

Fabrication of small-diameter vascular scaffolds by heparin-bonded P(LLA-CL) composite nanofibers to improve graft patency

Wang S, Mo XM, Jiang BJ, Gao CJ, Wang HS, Zhuang YG, Qiu LJ

International Journal of Nanomedicine 2013, 8:2131-2139

Published Date: 7 June 2013

Polyethylenimine600-β-cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells

Tong H, Wang C, Huang Y, Shi Q, Fernandes JC, Dai K, Tang G, Zhang X

International Journal of Nanomedicine 2013, 8:1935-1946

Published Date: 24 May 2013

Clinical significance of metallothioneins in cell therapy and nanomedicine

Sharma S, Rais A, Sandhu R, Nel W, Ebadi M

International Journal of Nanomedicine 2013, 8:1477-1488

Published Date: 16 April 2013